β1 integrin: An emerging player in the modulation of tumorigenesis and response to therapy

Cell Adhesion and Migration

Volumn 6, Issue 2, 2012, Pages 71-77

  Howe, Grant A ^a,b   Addison, Christina L ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

3D growth; Beta 1 integrin; Drug resistance; Fibronectin; Invasion; Matrix metalloproteinase; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FIBRONECTIN; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; GELATINASE B; MELPHALAN; PACLITAXEL; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR GLI1; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; DRUG RESPONSE; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; NONHUMAN; NOTE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RADIATION RESPONSE; TUMOR; TUMOR GROWTH;

MUS MUSCULUS;

EID: 84863968290     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.20077     Document Type: Note

References (93)

1. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110:673-87; PMID:12297042; http://dx.doi.org/10.1016/S0092-8674(02)00971-6
2. Fu G, Wang W, Luo BH. Overview: structural biology of integrins. Methods Mol Biol 2012; 757:81-99; PMID:21909908; http://dx.doi.org/10.1007/978-1-61779- 166-6-7
3. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69:11-25; PMID: 1555235; http://dx.doi.org/10.1016/0092- 8674(92)90115-S
4. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999; 71:435-78; PMID:10354709; http://dx.doi.org/10.1016/S0079-6107(98)00052-2
5. Chen LM, Bailey D, Fernandez-Valle C. Association of beta 1 integrin with focal adhesion kinase and paxillin in differentiating Schwann cells. J Neurosci 2000; 20:3776-84; PMID:10804218
6. Parsons JT, Parsons SJ. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol 1997; 9:187-92; PMID:9069259; http://dx.doi.org/10.1016/S0955-0674(97)80062-2
7. Guan JL. Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer. IUBMB Life 2010; 62:268-76; PMID:20101634
8. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006; 18:516-23; PMID:16919435; http://dx.doi.org/10.1016/j.ceb.2006.08.011
9. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 1996; 379:91-6; PMID:8538749; http://dx.doi.org/10.1038/379091a0
10. Hannigan GE, McDonald PC, Walsh MP, Dedhar S. Integrin-linked kinase: not so 'pseudo' after all. Oncogene 2011; 30:4375-85; PMID:21602880; http://dx.doi.org/10.1038/onc.2011.177
11. Wu C. Integrin-linked kinase and PINCH: partners in regulation of cell-extracellular matrix interaction and signal transduction. J Cell Sci 1999; 112:4485-9; PMID:10574698
12. Tu Y, Li F, Goicoechea S, Wu C. The LIM-only protein PINCH directly interacts with integrin-linked kinase and is recruited to integrin-rich sites in spreading cells. Mol Cell Biol 1999; 19:2425-34; PMID:10022929
13. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P. Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 2010; 10:858-70; PMID:21102636; http://dx.doi.org/10.1038/nrc2967
14. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009; 326:1216-9; PMID:19965464; http://dx.doi.org/10.1126/science.1176009
15. Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 2009; 17:153-62; PMID:19320882; http://dx.doi.org/10.1111/j.1524-475X.2009.00466.x
16. Schedin P, Keely PJ. Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb Perspect Biol 2011; 3:a003228; PMID:20980442; http://dx.doi.org/10.1101/ cshperspect.a003228
17. Watt FM, Fujiwara H. Cell-extracellular matrix interactions in normal and diseased skin. Cold Spring Harb Perspect Biol 2011; 3:a005124; PMID:21441589; http://dx.doi.org/10.1101/cshperspect.a005124
18. Hagedorn HG, Bachmeier BE, Nerlich AG. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (Review). [Review]. Int J Oncol 2001; 18:669-81; PMID:11251160
19. Lai KK, Shang S, Lohia N, Booth GC, Masse DJ, Fausto N, et al. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet 2011; 7:e1002147; PMID:21731504; http://dx.doi.org/10.1371/journal.pgen.1002147
20. Lochter A, Bissell MJ. Involvement of extracellular matrix constituents in breast cancer. Semin Cancer Biol 1995; 6:165-73; PMID:7495985; http://dx.doi.org/10.1006/scbi.1995.0017
21. Noel A, Kebers F, Maquoi E, Foidart JM. Cell-cell and cell-matrix interactions during breast cancer progression. Curr Top Pathol 1999; 93:183-93; PMID: 10339911; http://dx.doi.org/10.1007/978-3-642-58456-5-19
22. Jang YC, Arumugam S, Ferguson M, Gibran NS, Isik FF. Changes in matrix composition during the growth and regression of human hemangiomas. J Surg Res 1998; 80:9-15; PMID:9790808; http://dx.doi.org/10.1006/jsre.1998.5355
23. Nair SA, Nair MB, Jayaprakash PG, Rajalekshmy TN, Nair MK, Pillai MR. The basement membrane and tumor progression in the uterine cervix. Gen Diagn Pathol 1997; 142:297-303; PMID:9228252
24. Tuominen H, Kallioinen M. Increased tenascin expression in melanocytic tumors. J Cutan Pathol 1994; 21:424-9; PMID:7532653; http://dx.doi.org/10.1111/ j.1600-0560.1994.tb00284.x
25. Ramos DM, Chen B, Regezi J, Zardi L, Pytela R. Tenascin-C matrix assembly in oral squamous cell carcinoma. Int J Cancer 1998; 75:680-7; PMID: 9495234; http://dx.doi.org/10.1002/(SICI)1097-0215(19980302)75:5<680::AID-IJC4>3.0. CO;2-V
26. Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999; 20:749-55; PMID:10334190; http://dx.doi.org/10.1093/carcin/20.5.749
27. Kannan S, Balaram P, Chandran GJ, Pillai MR, Mathew B, Nalinakumari KR, et al. Alterations in expression of basement membrane proteins during tumour progression in oral mucosa. Histopathology 1994; 24:531-7; PMID:8063281; http://dx.doi.org/10.1111/j.1365-2559.1994.tb00571.x
28. Tosios KI, Kapranos N, Papanicolaou SI. Loss of basement membrane components laminin and type IV collagen parallels the progression of oral epithelial neoplasia. Histopathology 1998; 33:261-8; PMID: 9777393; http://dx.doi.org/10.1046/j.1365-2559.1998.00452.x
29. Albrecht M, Renneberg H, Wennemuth G, Möschler O, Janssen M, Aumüller G, et al. Fibronectin in human prostatic cells in vivo and in vitro: expression, distribution, and pathological significance. Histochem Cell Biol 1999; 112:51-61; PMID:10461812; http://dx.doi.org/10.1007/s004180050391
30. Nagle RB, Hao J, Knox JD, Dalkin BL, Clark V, Cress AE. Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. Am J Pathol 1995; 146:1498-507; PMID:7778688
31. Nagle RB. Role of the extracellular matrix in prostate carcinogenesis. J Cell Biochem 2004; 91:36-40; PMID: 14689579; http://dx.doi.org/10.1002/jcb.10692
32. Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL, et al. Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am J Pathol 1994; 145:167-74; PMID:8030747
33. Cress AE, Rabinovitz I, Zhu W, Nagle RB. The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev 1995; 14:219-28; PMID:8548870; http://dx.doi.org/10.1007/BF00690293
34. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ. Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 1997; 33:263-71; PMID:9135498; http://dx.doi.org/10.1016/ S0959-8049(96)00418-2
35. Pontes-Júnior J, Reis ST, de Oliveira LC, Sant'anna AC, Dall'oglio MF, Antunes AA, et al. Association between integrin expression and prognosis in localized prostate cancer. Prostate 2010; 70:1189-95; PMID: 20564421; http://dx.doi.org/10.1002/pros.21153
36. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KS, Cress AE. Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines. J Cancer Res Clin Oncol 1993; 119:637-44; PMID:7688749; http://dx.doi.org/10.1007/BF01215981
37. Nyga A, Cheema U, Loizidou M. 3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun Signal 2011; 5:239-48; PMID:21499821; http://dx.doi.org/10.1007/s12079-011-0132-4
38. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007; 4:359-65; PMID:17396127; http://dx.doi.org/10.1038/nmeth1015
39. Schooley AM, Andrews NM, Zhao H, Addison CL. β1 integrin is required for anchorage-independent growth and invasion of tumor cells in a context dependent manner. Cancer Lett 2012; 316:157-67; PMID:22099877; http://dx.doi.org/10.1016/j.canlet.2011.10.032
40. Goel HL, Underwood JM, Nickerson JA, Hsieh CC, Languino LR. Beta1 integrins mediate cell proliferation in three-dimensional cultures by regulating expression of the sonic hedgehog effector protein, GLI1. J Cell Physiol 2010; 224:210-7; PMID:20333644
41. Kocgozlu L, Lavalle P, Koenig G, Senger B, Haikel Y, Schaaf P, et al. Selective and uncoupled role of substrate elasticity in the regulation of replication and transcription in epithelial cells. J Cell Sci 2010; 123:29-39; PMID:20016064; http://dx.doi.org/10.1242/jcs.053520
42. Gilbert PM, Havenstrite KL, Magnusson KE, Sacco A, Leonardi NA, Kraft P, et al. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science 2010; 329:1078-81; PMID:20647425; http://dx.doi.org/10.1126/ science.1191035
43. Holst J, Watson S, Lord MS, Eamegdool SS, Bax DV, Nivison-Smith LB, et al. Substrate elasticity provides mechanical signals for the expansion of hemopoietic stem and progenitor cells. Nat Biotechnol 2010; 28:1123-8; PMID:20890282; http://dx.doi.org/10.1038/nbt.1687
44. Du J, Chen X, Liang X, Zhang G, Xu J, He L, et al. Integrin activation and internalization on soft ECM as a mechanism of induction of stem cell differentiation by ECM elasticity. Proc Natl Acad Sci U S A 2011; 108:9466-71; PMID:21593411; http://dx.doi.org/10.1073/pnas.1106467108
45. Wei WC, Lin HH, Shen MR, Tang MJ. Mechanosensing machinery for cells under low substratum rigidity. Am J Physiol Cell Physiol 2008; 295:C1579-89; PMID:18923058; http://dx.doi.org/10.1152/ajpcell.00223.2008
46. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U, et al. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004; 6:159-70; PMID:15324699; http://dx.doi.org/10.1016/j.ccr.2004.06.025
47. Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC, et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci U S A 2007; 104:20302-7; PMID:18056629; http://dx.doi.org/10.1073/pnas.0710091104
48. Huck L, Pontier SM, Zuo DM, Muller WJ. beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci U S A 2010; 107:15559-64; PMID:20713705; http://dx.doi.org/10.1073/pnas.1003034107
49. Noël A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008; 19:52-60; PMID:17625931; http://dx.doi.org/10.1016/j.semcdb.2007.05.011
50. Bourboulia D, Stetler-Stevenson WG. Matrix metallo-proteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010; 20:161-8; PMID:20470890; http://dx.doi.org/10.1016/j.semcancer.2010.05.002
51. Cruz-Munoz W, Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008; 45:291-338; PMID:18568853; http://dx.doi.org/10.1080/10408360801973244
52. Maity G, Choudhury PR, Sen T, Ganguly KK, Sil H, Chatterjee A. Culture of human breast cancer cell line (MDA-MB-231) on fibronectin-coated surface induces pro-matrix metalloproteinase-9 expression and activity. Tumour Biol 2011; 32:129-38; PMID:20821288; http://dx.doi.org/10.1007/s13277-010-0106-9
53. Sen T, Dutta A, Maity G, Chatterjee A. Fibronectin induces matrix metalloproteinase-9 (MMP-9) in human laryngeal carcinoma cells by involving multiple signaling pathways. Biochimie 2010; 92:1422-34; PMID:20638438; http://dx.doi.org/10.1016/j.biochi.2010.07.005
54. Esparza J, Vilardell C, Calvo J, Juan M, Vives J, Urbano-Márquez A, et al. Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood 1999; 94:2754-66; PMID: 10515879
55. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A 2004; 101:10602-7; PMID:15249664; http://dx.doi.org/10.1073/pnas.0404100101
56. Yang C, Zeisberg M, Lively JC, Nyberg P, Afdhal N, Kalluri R. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res 2003; 63:8312-7; PMID:14678990
57. Knutson JR, Iida J, Fields GB, McCarthy JB. CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol Biol Cell 1996; 7:383-96; PMID:8868467
58. Vihinen P, Riikonen T, Laine A, Heino J. Integrin alpha 2 beta 1 in tumorigenic human osteosarcoma cell lines regulates cell adhesion, migration, and invasion by nteraction with type I collagen. Cell Growth Differ 1996; 7:439-47; PMID:9052985
59. Tysnes BB, Larsen LF, Ness GO, Mahesparan R, Edvardsen K, Garcia-Cabrera I, et al. Stimulation of glioma-cell migration by laminin and inhibition by anti-alpha3 and anti-beta1 integrin antibodies. Int J Cancer 1996; 67:777-84; PMID:8824548; http://dx.doi.org/10.1002/(SICI)1097-0215(19960917)67:6<777:: AID-IJC5>3.0.CO;2-O
60. Deryugina EI, Bourdon MA. Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci 1996; 109:643-52; PMID:8907709
61. Fishman DA, Kearns A, Chilukuri K, Bafetti LM, O'Toole EA, Georgacopoulos J, et al. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen. Invasion Metastasis 1998; 18:15-26; PMID:10207247; http://dx.doi.org/10.1159/ 000024495
62. Masumoto A, Arao S, Otsuki M. Role of beta1 integrins in adhesion and invasion of hepatocellular carcinoma cells. Hepatology 1999; 29:68-74; PMID: 9862852; http://dx.doi.org/10.1002/hep.510290146
63. Caswell PT, Spence HJ, Parsons M, White DP, Clark K, Cheng KW, et al. Rab25 associates with alpha5-beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell 2007; 13:496-510; PMID:17925226; http://dx.doi.org/10.1016/j.devcel.2007.08.012
64. Juliano RL. The role of beta 1 integrins in tumors. Semin Cancer Biol 1993; 4:277-83; PMID:7504957
65. Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R, et al. The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 2000; 87:336-42; PMID: 10897037; http://dx.doi.org/10.1002/1097-0215(20000801)87: 3<336::AID-IJC5>3.0.CO;2-3
66. Davidson B, Goldberg I, Reich R, Tell L, Dong HP, Trope' CG, et al. AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 2003; 90:248-57; PMID:12893184; http://dx.doi.org/10.1016/S0090-8258(03)00321-4
67. Indra I, Beningo KA. An in vitro correlation of metastatic capacity, substrate rigidity, and ECM composition. J Cell Biochem 2011; 112:3151-8; PMID: 21732405; http://dx.doi.org/10.1002/jcb.23241
68. Matsuura N, Puzon-McLaughlin W, Irie A, Morikawa Y, Kakudo K, Takada Y. Induction of experimental bone metastasis in mice by transfection of integrin alpha 4 beta 1 into tumor cells. Am J Pathol 1996; 148:55-61; PMID:8546226
69. Nishimura S, Chung YS, Yashiro M, Inoue T, Sowa M. Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma. Br J Cancer 1996; 74:1406-12; PMID:8912536; http://dx.doi.org/10.1038/bjc.1996.556
70. Tani N, Higashiyama S, Kawaguchi N, Madarame J, Ota I, Ito Y, et al. Expression level of integrin alpha 5 on tumour cells affects the rate of metastasis to the kidney. Br J Cancer 2003; 88:327-33; PMID:12610521; http://dx.doi.org/10.1038/sj.bjc.6600710
71. Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, et al. Reduction in druginduced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 2001; 98:1897-903; PMID:11535527; http://dx.doi.org/10.1182/blood.V98.6.1897
72. Taylor ST, Hickman JA, Dive C. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst 2000; 92:18-23; PMID:10620629; http://dx.doi.org/10.1093/jnci/ 92.1.18
73. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5:662-8; PMID:10371505; http://dx.doi.org/10.1038/9511
74. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci (Lond) 2002; 102:417-24; PMID:11914104; http://dx.doi.org/10.1042/CS20010216
75. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001; 20:4995-5004; PMID:11526484; http://dx.doi.org/10.1038/sj.onc.1204554
76. Cordes N, Blaese MA, Meineke V, Van Beuningen D. Ionizing radiation induces up-regulation of functional beta1-integrin in human lung tumour cell lines in vitro. Int J Radiat Biol 2002; 78:347-57; PMID:12020426; http://dx.doi.org/10.1080/09553000110117340
77. Cordes N, van Beuningen D. Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase-3beta (GSK-3beta) in vitro. Br J Cancer 2003; 88: 1470-9; PMID:12778079; http://dx.doi.org/10.1038/ sj.bjc.6600912
78. Cordes N, Seidler J, Durzok R, Geinitz H, Brakebusch C. beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 2006; 25:1378-90; PMID:16247454; http://dx.doi.org/10.1038/sj.onc.1209164
79. Hodkinson PS, Elliott T, Wong WS, Rintoul RC, Mackinnon AC, Haslett C, et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ 2006; 13:1776-88; PMID:16410797; http://dx.doi.org/10.1038/sj.cdd.4401849
80. Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ. Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res 2008; 68:4398-405; PMID:18519702; http://dx.doi.org/10.1158/0008- 5472.CAN-07-6390
81. Eke I, Cordes N. Radiobiology goes 3D: how ECM and cell morphology impact on cell survival after irradiation. Radiother Oncol 2011; 99:271-8; PMID: 21704412; http://dx.doi.org/10.1016/j.radonc.2011.06.007
82. Yau CY, Wheeler JJ, Sutton KL, Hedley DW. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005; 65:1497-504;PMID:15735038; http://dx.doi.org/10. 1158/0008-5472.CAN-04-2940
83. Wong RP, Ng P, Dedhar S, Li G. The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth. Mol Cancer Ther 2007; 6:1692-700; PMID:17575101; http://dx.doi.org/10.1158/1535-7163.MCT-07-0134
84. Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, et al. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol Cancer Ther 2008; 7:59-70; PMID: 18202010; http://dx.doi.org/10.1158/1535-7163.MCT-07-0329
85. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res 2006; 66:393-403; PMID:16397254; http://dx.doi.org/10.1158/0008-5472. CAN-05-2304
86. Walsh C, Tanjoni I, Uryu S, Tomar A, Nam JO, Luo H, et al. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther 2010; 9:778-90; PMID:20234193; http://dx.doi.org/10.4161/cbt.9.10.11433
87. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, et al. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008; 51:7405-16; PMID:18989950; http://dx.doi.org/10.1021/jm800483v
88. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008; 68:1935-44; PMID:18339875; http://dx.doi.org/10.1158/0008-5472.CAN-07-5155
89. Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 2007; 46:488-96; PMID: 17219439; http://dx.doi.org/10.1002/mc.20297
90. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007; 67:10976-83; PMID: 18006843; http://dx.doi.org/10.1158/0008-5472.CAN-07-2667
91. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 2009; 8:2435-43; PMID:19571674; http://dx.doi.org/10.4161/cc. 8.15.9145
92. Färber K, Synowitz M, Zahn G, Vossmeyer D, Stragies R, van Rooijen N, et al. An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci 2008; 39:579-85; PMID:18804537; http://dx.doi.org/10.1016/j.mcn.2008. 08.005
93. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003; 104:496-503; PMID:12584749; http://dx.doi.org/10.1002/ijc.10958